Physician profile
Ruchir Patel
NPI 1285810630
$5,028.19
in general payments reported to CMS, 2019-2025
27 companies · $592 in 2025
The $592 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $430 · 2021: $294 · 2022: $1,028 · 2023: $782 · 2024: $693 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,360.27 | 2019-2025 | |
| Boston Scientific Corporation | $614.02 | 2019-2025 | Spyglass Discover, Spyglass, Axios |
| Janssen Scientific Affairs, LLC | $355.91 | 2022-2025 | Stelara, Tremfya, Remicade |
| Abiomed | $289.69 | 2019-2025 | |
| Medtronic, INC. | $251.66 | 2022-2024 | Gi Genius |
| Janssen Biotech, INC. | $194.06 | 2024-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $181.00 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $154.47 | 2022 | |
| Ardelyx, INC. | $151.04 | 2023-2024 | Ibsrela |
| Pfizer INC. | $145.00 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $143.31 | 2021 | |
| Ferring Pharmaceuticals INC. | $132.89 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $125.38 | 2024 | Voquezna |
| Shionogi INC | $125.01 | 2020 | |
| Evoke Pharma, INC. | $119.81 | 2023 | Gimoti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $119.22 | 2023 | Imfinzi |
| Medtronic Vascular, INC. | $118.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.98 | 2019 | |
| Qol Medical, LLC | $66.74 | 2019-2023 | Sucraid |
| Covidien LP | $61.31 | 2019 | |
| Abbott Laboratories | $49.29 | 2023-2025 | Mitraclip, Cardiomems |
| Imperative Care, INC | $34.85 | 2024 | Hotshot Controller |
| Ethicon US, LLC | $33.72 | 2019 | |
| Genzyme Corporation | $30.79 | 2023 | |
| Aimmune Therapeutics, INC. | $21.51 | 2024 | |
| 3b Medical, INC. | $19.47 | 2025 | Luna |
| Apollo Endosurgery US INC | $19.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchir Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.